Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by LEO Pharma

< Previous 1 2 Next >
LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
From LEO Pharma
Via Business Wire
LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years
From LEO Pharma
Via Business Wire
LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
From LEO Pharma
Via Business Wire
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
From LEO Pharma
Via Business Wire
Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial
From LEO Pharma
Via Business Wire
Globally Known Professor and Dermatologist Joins LEO Pharma
From LEO Pharma
Via Business Wire
LEO Pharma delivers solid first half-year results and strengthens its capital structure
From LEO Pharma
Via Business Wire
LEO Pharma announces changes to its Global Leadership Team
From LEO Pharma
Via Business Wire
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
From LEO Pharma
Via Business Wire
EMA Accepts LEO Pharma’s Marketing Authorization Application (MAA) for Delgocitinib Cream in Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023
From LEO Pharma
Via Business Wire
LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting
From LEO Pharma
Via Business Wire
LEO Pharma Adds Internationally Recognized Dermatologist to Global Leadership Team
From LEO Pharma
Via Business Wire
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
From LEO Pharma
Via Business Wire
LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial
From LEO Pharma
Via Business Wire
LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Launches AD Days Around the World Campaign to Raise Awareness of the Impact of Atopic Dermatitis Across Cultures
From LEO Pharma
Via Business Wire
LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis
From LEO Pharma
Via Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress
From LEO Pharma
Via Business Wire
LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe atopic dermatitis at 31st EADV Congress
From LEO Pharma
Via Business Wire
LEO Pharma Appoints Paul Navarre New Member of Its Board of Directors
From LEO Pharma
Via Business Wire
LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology
From LEO Pharma
Via Business Wire
LEO Pharma Strengthens Its Commercial Organization
From LEO Pharma
Via Business Wire
LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
From LEO Pharma
Via Business Wire
LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)
From LEO Pharma
Via Business Wire
Adtralza® (tralokinumab) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.